Medicare beneficiaries seeking affordable access to weight-loss drugs will have to wait longer after major insurers refused to participate in a federal pilot program. The Centers for Medicare and Medicaid Services (CMS) has indefinitely postponed the BALANCE financing model. Insurance giants like CVS have declined to participate, according to a note from Truist Securities. This delay impacts the coverage of GLP-1 drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Without the pilot, many older adults must continue to pay out-of-pocket prices that can exceed $1,000 a month. Telehealth platforms like Him & Hers have begun offering semaglutide for as low as $149 per month, but these are cash-pay options outside of government insurance. Meanwhile, the FDA has issued a warning letter to New Life Pharma after inspectors were barred from entering sections of a GLP-1 manufacturing site. The manufacturer claimed inspectors lacked the authority to see areas labeled "Area Not in Use." As the metabolic divide widens, generic versions of these drugs are selling for $15 a month in the Global South, while the American working class remains locked behind a corporate subscription model.